Targeting angiogenesis in cancer therapy: Moving beyond vascular endothelial growth factor

Oncologist

Volumn 20, Issue 6, 2015, Pages 660-673

  Zhao, Yujie ^a   Adjei, Alex A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis inhibitors; Antibodies, monoclonal, humanized; Fibroblast growth factor; Molecular targeted therapy; Platelet derived growth factor; Receptors; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; AXITINIB; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; DOCETAXEL; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NINTEDANIB; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAMUCIRUMAB; REGORAFENIB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ABDOMINAL PAIN; ANGIOGENESIS; APPETITE DISORDER; ARTICLE; BACKACHE; BINDING AFFINITY; BREAST CANCER; CANCER THERAPY; CELL PROLIFERATION; DIARRHEA; DRUG TOLERABILITY; DRY SKIN; DYSPHONIA; EPISTAXIS; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; LACRIMATION DISORDER; LEUKOPENIA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RECTUM HEMORRHAGE; RHINITIS; SIGNAL TRANSDUCTION; STOMATITIS; SYSTEMATIC REVIEW; TASTE DISORDER; THROMBOCYTOPENIA; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANGIOGENESIS INHIBITORS; FIBROBLAST GROWTH FACTORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84932616956     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0465     Document Type: Article

References (146)

1. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nature Rev Drug Discov 2007;6:273–286.
2. Kieran MW, Kalluri R, Cho YJ. The VEGF pathway in cancer and disease: Responses, resistance, and the path forward. Cold Spring Harb Perspect Med 2012;2:a006593.
3. Hicklin DJ, Ellis LM. Role of the vascular endo-thelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–1027.
4. Carmeliet P, Jain RK. Molecularmechanismsand clinical applications of angiogenesis. Nature 2011; 473:298–307.
5. Avastin [prescribing information]. South San Francisco, CA: Genentech; 2014.
6. Inlyta [package insert]. New York, NY: Pfizer, Inc.; 2013.
7. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
8. Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306–1309.
9. Tischer E, Gospodarowicz D, Mitchell R et al. Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 1989;165: 1198–1206.
10. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2009; 2:re1.
11. Dvorak HF. Vascular permeability factor/ vascular endothelial growth factor: A critical cyto-kine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20: 4368–4380.
12. Fischer C, Mazzone M, Jonckx B et al. FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8: 942–956.
13. De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012;44:1–9.
14. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010;140:460–476.
15. Ferrara N, Hillan KJ, Gerber HP et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391–400.
16. FDA commissioner announces Avastin deci-sion.Availableat http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280536. htm. Accessed May 5, 2015.
17. Kristensen TB, Knutsson ML, Wehland M et al. Anti-vascular endothelial growth factor therapy in breast cancer. Int J Mol Sci 2014;15: 23024–23041.
18. Mortimer J, Zonder HB, Pal SK. Lessons learned from the bevacizumab experience. Cancer Contr 2012;19:309–316.
19. Shojaei F. Anti-angiogenesis therapy incancer: Current challenges and future perspectives. Cancer Lett 2012;320:130–137.
20. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610–2621.
21. Paéz-Ribes M, Allen E, Hudock J et al. Anti-angiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220–231.
22. Chen HX, Cleck JN. Adverse effects of antican-cer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465–477.
23. Loupakis F, Cremolini C, Fioravanti A et al. Pharmacodynamic and pharmacogenetic angiogen-esis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011;104:1262–1269.
24. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009;43:490–501.
25. Holash J, Davis S, Papadopoulos N et al. VEGF-Trap:A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393–11398.
26. Gomez-Manzano C, Holash J, Fueyo J et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 2008;10:940–945.
27. Kim ES, Serur A, Huang J et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 2002;99:11399–11404.
28. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic col-orectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499–3506.
29. Fuchs CS, Tomasek J, Yong CJ et al. Ramucir-umab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarci-noma(REGARD):Aninternational,randomised,multi-centre,placebo-controlled,phase3trial. Lancet 2014; 383:31–39.
30. Wilke H, Muro K, Van Cutsem E et al. Ramucir-umab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224–1235.
31. Spratlin J. Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Rep 2011;13: 97–102.
32. Aprile G, Bonotto M, Ongaro E et al. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: From benchside to clinical use. Drugs 2013;73:2003–2015.
33. Garon EB, Ciuleanu T-E, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IVnon-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384:665–673.
34. Mackey JR, Ramos-Vazquez M, Lipatov O et al. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol 2015; 33:141–148.
35. Zhu AX, Ryoo BY, Yen CJ et al. Ramucirumab (RAM) as a second-line treatment in patients (PTS) with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: Results from the randomized phase III REACH study. Ann Oncol 2014;25(suppl 5):LBA16a.
36. Ferrara N. PathwaysmediatingVEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010;21:21–26.
37. Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal 2013;11:97.
38. Wu E, Palmer N, Tian Z et al. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One 2008;3: e3794.
39. Cao Y. Multifarious functions of PDGFs and PDGFRsintumorgrowthandmetastasis.TrendsMol Med 2013;19:460–473.
40. Levitzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev 2004;15:229–235.
41. Tejada ML, Yu L, Dong J et al. Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res 2006;12:2676–2688.
42. Ding W, Knox TR, Tschumper RC et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: Implications for an angio-genic switch. Blood 2010;116:2984–2993.
43. Cao R, Björndahl MA, Religa P et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004;6: 333–345.
44. Kodama M, Kitadai Y, Sumida T et al. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor b is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci 2010;101:1984–1989.
45. Xue Y, Lim S, Yang Y et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med 2012;18:100–110.
46. Lu C, Shahzad MM, Moreno-Smith M et al. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 2010;9:176–182.
47. Beenken A, Mohammadi M. The FGF family: Biology, pathophysiology and therapy.Nat Rev Drug Discov 2009;8:235–253.
48. Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010;70:2085–2094.
49. Cao Y, Cao R, Hedlund EM. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways.JMolMed (Berl) 2008;86: 785–789.
50. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002;8:483–489.
51. Presta M, Dell’Era P, Mitola S et al. Fibroblast growth factor/fibroblast growth factor receptor systeminangiogenesis.Cytokine GrowthFactor Rev 2005;16:159–178.
52. Cao R, Ji H, Feng N et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangio-genesisandmetastasis.ProcNatlAcadSciUSA2012; 109:15894–15899.
53. Huang H, Bhat A, Woodnutt G et al.Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010;10:575–585.
54. Giavazzi R, Sennino B, Coltrini D et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 2003;162:1913–1926.
55. Casanovas O, Hicklin DJ, Bergers G et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299–309.
56. Cascone T, Heymach JV. Targeting the angiopoietin/Tie2 pathway: Cutting tumor vessels with a double-edged sword? J Clin Oncol 2012;30: 441–444.
57. Tait CR, Jones PF. Angiopoietins in tumours: The angiogenic switch. J Pathol 2004;204:1–10.
58. Gerald D, Chintharlapalli S, Augustin HG et al. Angiopoietin-2: An attractive target for improved antiangiogenic tumor therapy. Cancer Res 2013;73: 1649–1657.
59. Graveel CR, Tolbert D, Vande Woude GF. MET: A critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol 2013;5: 9209.
60. You WK, McDonald DM. The hepatocyte growth factor/c-Met signaling pathway as a thera-peutictargettoinhibitangiogenesis.BMBRep 2008; 41:833–839.
61. Wojta J, Kaun C, Breuss JM et al. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest 1999;79: 427–438.
62. Lu KV, Chang JP, Parachoniak CA et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012;22:21–35.
63. Jahangiri A, De Lay M, Miller LM et al. Gene expressionprofile identifiestyrosine kinasec-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 2013;19:1773–1783.
64. Mulligan LM. RET revisited: Expanding the oncogenic portfolio. Nat Rev Cancer 2014;14:173–186.
65. Ibáñez CF. Structure and physiologyofthe RET receptor tyrosine kinase. Cold Spring Harb Perspect Biol 2013;5:9134.
66. Elisei R, Schlumberger MJ, Müller SP et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31:3639–3646.
67. Kurzrock R, Sherman SI, Ball DW et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor,inpatients with medullarythyroid cancer. J Clin Oncol 2011;29:2660–2666.
68. Wells SA Jr., Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastaticmedullary thyroid cancer:Arandomized, double-blind phase III trial. J Clin Oncol 2012;30: 134–141.
69. Crinó L, Metro G. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur Respir Rev 2014;23:79–91.
70. Ballas MS, Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther 2011;4:43–58.
71. Welti J, Loges S, Dimmeler S et al. Recent molecular discoveries in angiogenesis and antian-giogenic therapies in cancer. J Clin Invest 2013;123: 3190–3200.
72. Kopetz S, Hoff PM, Morris JS et al. Phase II trial of infusional fluorouracil, irinotecan, and bevaci-zumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010;28: 453–459.
73. Lieu CH, Tran H, Jiang ZQ et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One 2013;8:e77117.
74. Clarke JM, Hurwitz HI. Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol 2013;4:253–263.
75. Ebos JM, Kerbel RS. Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210–221.
76. Loges S, Mazzone M, Hohensinner P et al. Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 2009;15: 167–170.
77. Bergers G, Song S, Meyer-Morse N et al. Benefits of targeting both pericytes and endothelial cellsin the tumorvasculature with kinase inhibitors. J Clin Invest 2003;111:1287–1295.
78. Erber R, Thurnher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regressionbyinterfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338–340.
79. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83–95.
80. Wilmes LJ, Pallavicini MG, Fleming LM et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007;25: 319–327.
81. Cometriq [package insert]. South San Francisco, CA; Exelixis, Inc. 2012.
82. Hilberg F, Roth GJ, Krssak M et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774–4782.
83. Votrient [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013.
84. Stivarga [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2013.
85. Nexavar [package insert]. South San Francisco, CA: Bayer HealthCare Pharmaceuticals, Inc.; 2013.
86. Sutent [package insert]. New York, NY: Pfizer; 2013.
87. Caprelsa [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2013.
88. Chau NG, Haddad RI. Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res 2013;19:524–529.
89. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS):Arandomised phase 3 trial. Lancet 2011;378:1931–1939.
90. Reck M, Kaiser R, Mellemgaard A et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143–155.
91. Hanna NH, Kaiser R, Sullivan RN et al. LUME-lung 2: A multicenter, randomized, double-blind, phaseIIIstudyofnintedanibpluspemetrexedversus placebo plus pemetrexed inpatients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013;31:8034a.
92. Du Bois A, Kristensen G, Ray-Coquard I et al. AGO-OVAR 12: A randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy 1/2 nintedanib for advanced ovariancancer.IntJGynecol Cancer 2013;23 (suppl 1):7.
93. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061–1068.
94. van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879–1886.
95. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303–312.
96. Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295–302.
97. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312–3318.
98. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib inadvanced hepatocellular carcinoma.NEnglJMed 2008;359:378–390.
99. Brose MS, Nutting CM, Jarzab B et al.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet 2014;384: 319–328.
100. Demetri GD, Garrett CR, Schöffski P et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 2012;18: 3170–3179.
101. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–124.
102. Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14:552–562.
103. Sternberg CN, Hawkins RE, Wagstaff J et al. A randomised, double-blind phase III study of pazo-panib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. Eur J Cancer 2013;49:1287–1296.
104. Griffioen AW, Mans LA, de Graaf AM et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 2012;18:3961–3971.
105. Majumder S, Piguet AC, Dufour JF et al. Study of the cellular mechanism of sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. Eur J Pharmacol 2013; 705:86–95.
106. Olson P, Chu GC, Perry SR et al. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrinebut notductalcarcinoma.ProcNatl Acad Sci USA 2011;108:E1275–E1284.
107. Chang YS, Adnane J, Trail PA et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascular-ization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561–574.
108. Kim S, Yazici YD, Calzada G et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007;6:1785–1792.
109. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogene-sis, and induces tumor cell apoptosis in hepatocel-lular carcinoma model PLC/PRF/5. Cancer Res 2006; 66:11851–11858.
110. Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. The Oncologist 2010;15:539–547.
111. Abou-Elkacem L, Arns S, Brix G et al. Regor-afenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 2013;12:1322–1331.
112. Cyran CC, Kazmierczak PM, Hirner H et al. Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation. PLoS One 2013;8:e76009.
113. CHMP summary of positive opinion for Varga-tef. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002569/WC500173607. pdf. Accessed May 5, 2015.
114. Mross K, Stefanic M, Gmehling D et al. PhaseI study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311–319.
115. Reck M. BIBF 1120 for the treatment of non-small cell lung cancer. Expert Opin Investig Drugs 2010;19:789–794.
116. Okamoto I, Kaneda H, Satoh T et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010;9:2825–2833.
117. Kudo K, Arao T, Tanaka K et al. Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR21pTyr1 peripheral blood leukocytesasapharmacodynamicbiomarkerinvivo. Clin Cancer Res 2011;17:1373–1381.
118. Eisen T, Shparyk Y, Macleod N et al. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) onQTinterval inpatients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Invest New Drugs 2013;31:1283–1293.
119. Doebele RC, Conkling P, Traynor AM et al. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120incombination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2012;23:2094–2102.
120. Bousquet G, Alexandre J, Le Tourneau C et al. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. Br J Cancer 2011;105:1640–1645.
121. Ellis PM, Kaiser R, Zhao Y et al. Phase I open-label studyofcontinuoustreatmentwith BIBF1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010;16:2881–2889.
122. du Bois A, Huober J, Stopfer P et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 2010;21:370–375.
123. Johnson PJ, Qin S, Park JW et al. Brivanib versus sorafenibasfirst-line therapyinpatients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31:3517–3524.
124. Cai ZW, Zhang Y, Borzilleri RM et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008; 51:1976–1980.
125. Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-4400.
126. Angevin E, Lopez-Martin JA, Lin CC et al. Phase Istudyofdovitinib(TKI258), anoralFGFR,VEGFR,and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 2013;19:1257-1268.
127. Matsui J, Funahashi Y, Uenaka T et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14:5459-5465.
128. Matsui J, Yamamoto Y, Funahashi Y et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122:664-671.
129. Cainap C, Qin S, Huang WT et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. J Clin Oncol 2015;33:172-179.
130. Zhou J, Goh BC, Albert DH et al. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedside. J Hematol Oncol 2009;2:33.
131. Hoff PM, Hochhaus A, Pestalozzi BC et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: A randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 2012;30:3596-3603.
132. Schmoll HJ, Cunningham D, Sobrero A et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III). J Clin Oncol 2012;30:3588-3595.
133. Batchelor TT, Mulholland P, Neyns B et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31:3212-3218.
134. Ledermann JA, Perren TJ, Raja FA et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial [abstract E17-7020]. Presented at: ECCO-ESMO-ESTRO European Cancer Congress; September 27-October 1, 2013; Amsterdam, The Netherlands.
135. Laurie SA, Solomon BJ, Seymour L et al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer 2014;50:706-712.
136. Motzer RJ, Porta C, Vogelzang NJ et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3trial. Lancet Oncol 2014;15:286-296.
137. Schlumberger MJ, Tahara M, Wirth LJ et al. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 2014;32:LBA6008a.
138. Stopfer P, Rathgen K, Bischoff D et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 2011; 41:297-311.
139. Sahade M, Caparelli F, Hoff PM. Cediranib: A VEGF receptor tyrosine kinase inhibitor. Future Oncol 2012;8:775-781.
140. Sonpavde G, Willey CD, Sudarshan S. Fibroblast growth factor receptorsastherapeutic targets in clear-cell renal cell carcinoma. Expert Opin Investig Drugs 2014;23:305-315.
141. Sun H, Zhu MS, Wu WR et al. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. World J Hepatol 2014;6:830-835.
142. Zhu AX. New agents on the horizon in hepatocellular carcinoma. Ther Adv Med Oncol 2013;5:41-50.
143. Gligorov J, Doval D, Bines J et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (I MELDA): A randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1351-1360.
144. von Minckwitz G, Puglisi F, Cortes J et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1269-1278.
145. Wehland M, Bauer J, Magnusson NE et al. Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci 2013;14:9338-9364.
146. Pilotto S, Bonomi M, Massari F et al. Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: A ‘hard days night’. Curr Pharm Des 2014;20:3958-3972.